FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236861311> ?p ?o ?g. }

• W4236861311 endingPage "316" @default.
• W4236861311 startingPage "316" @default.
• W4236861311 abstract "Abstract CD4+CD25+ regulatory T cells (Tr) are negative regulators of immune responses. Studies of human Tr are restricted by their small numbers in peripheral blood and their hypoproliferative state. A recently established method achieved in vitro expansion and generation of Tr cell lines (Godfrey et al; Blood 2004,104:453-61). This approach facilitates the evaluation of cultured Tr cells as a novel form of immunosuppressive therapy and provides a system for molecular analysis of Tr. Activation of Ras and MAP kinases is mandatory for IL-2 production, viability and cell cycle progression of T cells. In anergic T cells activation of these signaling events is impaired, whereas activation of Rap1 is retained. Subsequently, anergic cells have defective IL-2 production, impaired cell cycle progression, and increased susceptibility to apoptosis. In the current study, we sought to determine the signaling and biochemical properties of Tr. Human CD4+CD25+ (Tr) and control CD4+CD25− (Tc) cell lines were generated from human cord blood cells. We examined activation of Ras, Rap1 and MAP kinases as well as cell cycle progression and cell viability, in response to TCR/CD3-plus-CD28 mediated stimulation. Stimulation was done for 15 min, 2 and 16 hrs for assessment of signaling events or for 24, 48 and 72 hrs for assessment of cell cycle progression and viability. Although activation of Rap1 was not affected, activation of Ras was reduced in Tr as compared to Tc. Activation of JNK and Erk1/2 MAP kinases was also significantly impaired. Both Tr and Tc entered the cell cycle and expressed cyclin E and cyclin A at 24 and 48 hrs of culture. However, p27 was downregulated only in Tc and not in Tr and hyperphosphorylation of Rb, which is the hallmark of cell cycle progression, was detected only in the Tc and not in the Tr population. At 72 hrs of culture, expression of cyclin E and cyclin A was dramatically diminished in Tr whereas it remained unchanged in Tc. More strikingly, expression of p27 in Tr was increased to levels higher than background. Since Tr do not produce IL-2, we examined whether addition of exogenous IL-2 would downregulate p27 and rescue Tr from defective cell cycle progression, similarly to its effect on anergic cells. Addition of exogenous IL-2 resulted in decrease of p27, sustained increase of cyclin E and cyclin A and cell cycle progression. Besides inhibiting cell cycle progression, p27 also promotes apoptosis. Therefore, we examined whether Tr had a higher susceptibility to apoptosis. As determined by Annexin V staining, Tr had a high degree of apoptosis only at 72 hrs of culture, when p27 expression was highly upregulated. Exogenous IL-2 reversed both p27 upregulation and apoptosis. Addition of IL-2 to Tr, also resulted in sustained IL-2-receptor-mediated activation of Erk1/2 at levels equivalent to those of Tc. Thus Tr cells share many biochemical and molecular characteristics of anergy, including defective TCR/CD3-plus-CD28-mediated activation of Ras and MAP kinases, increased expression of p27, defective cell cycle progression and high susceptibility to apoptosis. Moreover, these results suggest that TCR/CD3-mediated and IL-2 receptor-mediated signals converge at the level of MAP kinases to determine the fate of Tr cells towards expansion or cell cycle arrest and subsequent apoptosis." @default.
• W4236861311 created "2022-05-12" @default.
• W4236861311 creator A5003506732 @default.
• W4236861311 creator A5016169031 @default.
• W4236861311 creator A5027453053 @default.
• W4236861311 creator A5058268746 @default.
• W4236861311 creator A5076021568 @default.
• W4236861311 creator A5082227652 @default.
• W4236861311 creator A5088540790 @default.
• W4236861311 date "2004-11-16" @default.
• W4236861311 modified "2023-09-28" @default.
• W4236861311 title "CD4+CD25+ Regulatory T Cells from Cord Blood Have Functional and Molecular Properties of T Cell Anergy." @default.
• W4236861311 doi "https://doi.org/10.1182/blood.v104.11.316.316" @default.
• W4236861311 hasPublicationYear "2004" @default.
• W4236861311 type Work @default.
• W4236861311 citedByCount "0" @default.
• W4236861311 crossrefType "journal-article" @default.
• W4236861311 hasAuthorship W4236861311A5003506732 @default.
• W4236861311 hasAuthorship W4236861311A5016169031 @default.
• W4236861311 hasAuthorship W4236861311A5027453053 @default.
• W4236861311 hasAuthorship W4236861311A5058268746 @default.
• W4236861311 hasAuthorship W4236861311A5076021568 @default.
• W4236861311 hasAuthorship W4236861311A5082227652 @default.
• W4236861311 hasAuthorship W4236861311A5088540790 @default.
• W4236861311 hasConcept C148125776 @default.
• W4236861311 hasConcept C153911025 @default.
• W4236861311 hasConcept C167672396 @default.
• W4236861311 hasConcept C179464577 @default.
• W4236861311 hasConcept C184235292 @default.
• W4236861311 hasConcept C190283241 @default.
• W4236861311 hasConcept C19317047 @default.
• W4236861311 hasConcept C203014093 @default.
• W4236861311 hasConcept C2776090121 @default.
• W4236861311 hasConcept C2778296632 @default.
• W4236861311 hasConcept C2780914630 @default.
• W4236861311 hasConcept C53227056 @default.
• W4236861311 hasConcept C55493867 @default.
• W4236861311 hasConcept C79484868 @default.
• W4236861311 hasConcept C86803240 @default.
• W4236861311 hasConcept C8891405 @default.
• W4236861311 hasConcept C95444343 @default.
• W4236861311 hasConceptScore W4236861311C148125776 @default.
• W4236861311 hasConceptScore W4236861311C153911025 @default.
• W4236861311 hasConceptScore W4236861311C167672396 @default.
• W4236861311 hasConceptScore W4236861311C179464577 @default.
• W4236861311 hasConceptScore W4236861311C184235292 @default.
• W4236861311 hasConceptScore W4236861311C190283241 @default.
• W4236861311 hasConceptScore W4236861311C19317047 @default.
• W4236861311 hasConceptScore W4236861311C203014093 @default.
• W4236861311 hasConceptScore W4236861311C2776090121 @default.
• W4236861311 hasConceptScore W4236861311C2778296632 @default.
• W4236861311 hasConceptScore W4236861311C2780914630 @default.
• W4236861311 hasConceptScore W4236861311C53227056 @default.
• W4236861311 hasConceptScore W4236861311C55493867 @default.
• W4236861311 hasConceptScore W4236861311C79484868 @default.
• W4236861311 hasConceptScore W4236861311C86803240 @default.
• W4236861311 hasConceptScore W4236861311C8891405 @default.
• W4236861311 hasConceptScore W4236861311C95444343 @default.
• W4236861311 hasIssue "11" @default.
• W4236861311 hasLocation W42368613111 @default.
• W4236861311 hasOpenAccess W4236861311 @default.
• W4236861311 hasPrimaryLocation W42368613111 @default.
• W4236861311 hasRelatedWork W1979634385 @default.
• W4236861311 hasRelatedWork W2020054025 @default.
• W4236861311 hasRelatedWork W2032548247 @default.
• W4236861311 hasRelatedWork W2052520423 @default.
• W4236861311 hasRelatedWork W2147060984 @default.
• W4236861311 hasRelatedWork W2150662513 @default.
• W4236861311 hasRelatedWork W2158045591 @default.
• W4236861311 hasRelatedWork W2171838281 @default.
• W4236861311 hasRelatedWork W2288254884 @default.
• W4236861311 hasRelatedWork W2395867101 @default.
• W4236861311 hasVolume "104" @default.
• W4236861311 isParatext "false" @default.
• W4236861311 isRetracted "false" @default.
• W4236861311 workType "article" @default.